Paris, France – New York, USA – May 11 2023 – AI-powered search leader Sinequa has announced domain-specific enhancements to its intelligent search platform for Scientific Search and Clinical Trial Data. Its search platform now utilizes new Neural Search and ChatGPT capabilities for faster, more effective discovery and decisions in drug development and clinical research. Sinequa will present these capabilities at the 2023 Bio-IT World Conference, May 16-18, at the Boston Convention and Exhibition Center, during conference sessions and at booth #803 in Auditorium Hall C.
Combining the capabilities of Sinequa Neural Search – multiple deep learning and large language models for natural language understanding (NLU) – with the latest ChatGPT models through Azure OpenAI Service, Sinequa enables accurate, fast, traceable semantic search, insight generation, and summarization. Users can query and converse with a secure corpus of data, including proprietary life science systems, enterprise collaboration systems, and external data sources, to answer complex and nuanced questions. Comprehensive search results with best-in-class relevance and the ability to generate concise summaries enhance R&D intelligence, optimize clinical trials, and streamline regulatory workflows.
“The ability to harness AI for scientific and clinical trial data search creates tremendous opportunities for life sciences to radically improve the speed, scale, and efficacy of clinical research and drug development,” said Clifford Cantrell, Vice President, Global Life Science Practice Lead & Customer Success, Sinequa. “Building on more than 20 years of expertise in natural language processing and as one of the first providers to apply AI to enterprise search, Sinequa continues its legacy of proven innovation by bringing generative AI capabilities to clinical research and drug development.”
Today, more than half of the world’s leading pharmaceutical companies, including Astellas, AstraZeneca, Pfizer, Takeda, UCB, trust Sinequa to help teams discover insights and surface the information necessary to bring safe, life-changing therapies to market more quickly and with greater confidence.
